[1] 中华医学会心血管病学分会, 中华心血管病杂志编辑委员会. 急性ST段抬高型心肌梗死诊断和治疗指南(2019)[J]. 中华心血管病杂志, 2019, 47(10): 766-783.
[2] 吉娜, 郭治华. 不同年龄段急性心肌梗死病人临床特点分析[J]. 实用老年医学, 2018, 32(7): 630-633.
[3] NISHIKIMI T, MAEDA N, MATSUOKA H. The role of natriuretic peptides in cardioprotection[J]. Cardiovasc Res, 2006, 69(2): 318-328.
[4] 陈华. 新活素[J]. 中国新药杂志,2006,15(5): 393-394.
[5] 胡盛寿, 杨跃进, 郑哲,等. 《中国心血管病报告2018》概要[J]. 中国循环杂志, 2019, 34(3): 209-220.
[6] DU X, PATEL A, ANDERSON C S, et al. Epidemiology of cardiovascular disease in China and opportunities for improvement[J]. J Am Coll Cardiol, 2019, 73(24): 3135-3147.
[7] DESTA L, JERNBERG T, LOFMAN I, et al. Incidence, temporal trends, and prognostic impact of heart failure complicating acute myocardial infarction: the SWEDEHEART Registry (Swedish Web-System for enhancement and development of evidence-based care in heart disease evaluated according to recommended therapies): a study of 199,851 patients admitted with index acute myocardial infarctions, 1996 to 2008[J]. Jacc Heart Failure, 2015, 3(3): 234-242.
[8] STRAIN W D. The use of recombinant human B-type natriuretic peptide (nesiritide) in the management of acute decompensated heart failure[J]. Int J Clin Pract, 2004, 58(11): 1081-1087.
[9] HUNT S A. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult—summary article: a report of the american college of cardiology/American Heart Association Task Force on Practice Guidelines[J]. J Am Coll Cardiol, 2005, 46(6): e1-e82.
[10] 中华医学会心血管病学分会. 中国心力衰竭诊断和治疗指南2014[J]. 中华心血管病杂志, 2014, 42(2): 3-10.
[11] MICHAELS A D, KLEIN A, MADDEN J A, et al. Effects of intravenous nesiritide on human coronary vasomotor regulation and myocardial oxygen uptake[J]. Circulation, 2003, 107(21): 2697-2701.
[12] HILL J A, OLSON E N.Cardiac plasticity[J]. N Engl J Med, 2008, 358(13): 1370-1380.
[13] DIEPLINGER B, Mueller T.Soluble ST2 in heart failure[J]. Clin Chim Acta, 2015, 443:57-70.
[14] 曾艳, 谭华清, 唐湘宇, 等. 可溶性ST2与心血管疾病关系的研究进展[J]. 实用心脑肺血管病杂志, 2019, 27(5): 112-116.
[15] JANUZZI J L, PEACOCK P F, MAISEL A S, et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study[J]. J Am Coll Cardiol, 2007, 50(7):607-613.
[16] REHMAN S U, MARTINEZ-RUMAYOR A, MUELLER T, et al. Independent and incremental prognostic value of multimarker testing in acute dyspnea: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study[J]. Clin Chim Acta, 2008, 392 (1/2): 41-45.
[17] OLIVER P M, FOX J E, KIM R, et al. Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A[J]. ProcNatl Acad Sci U S A, 1997, 94(26): 14730-14735.
[18] UNVERZAGT S, BUERKE M, DE W A, et al. Intra-aortic balloon pump counterpulsation (IABP) for myocardial infarction complicated by cardiogenic shock[J]. Cochrane Database Syst Rev, 2015, 3(3): 7398. |
